Texas: Brook Jackson, a regional director for Ventavia Research Group that was conducting trials for Pfizer in Texas, told the British Medical Journal (BMJ) that Ventavia falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer's pivotal phase III trial. After she repeatedly notified Ventavia of the problems, she emailed a complaint to the US Food and Drug Administration (FDA), and was fired the same day. The FDA failed to inspect Ventavia after Jackson filed the complaint. Jackson blew the whistle and made her complaint to the FDA in September 2020, but the mainstream media has ignored this information. The FDA approved Pfizer's Covid vaccine on December 11, 2020.

In autumn 2020 Pfizer's chairman and chief executive, Albert Bourla, released an open letter to the billions of people around the world who were investing their hopes in a safe and effective covid-19 vaccine to end the pandemic. "As I've said before, we are operating at the speed of science," Bourla wrote, explaining to the public when they could expect a Pfizer vaccine to be authorised in the United States.1